Analysis of Anti Infection Effect of Piperacillin Tazobactam and Cefoperazone Sulbactam in Elderly Patients with Coronary Heart Disease

Abstract

Objective: to analyze the anti infection effect of piperacillin tazobactam and cefoperazone sulbactam in elderly patients with coronary heart disease. Methods: the experiment was carried out in groups from January 2019 to December 2020. The control group (cefoperazone sulbactam) and the study group (piperacillin tazobactam) were divided into two groups. The experimental patients were 98 elderly patients with coronary heart disease (49 cases in each group). Two groups of comparative indicators: pathogen clearance rate, incidence of adverse reactions. Results: the pathogen clearance rate of the study group was 94.63%, and that of the control group was 81.48%, which was higher than that of the control group (P < 0.05). The incidence of adverse reactions was 3.57% in the study group and 16.33% in the control group, which was lower in the study group than in the control group (P < 0.05). Conclusion: piperacillin tazobactam is better than cefoperazone sulbactam in the treatment of anti infection in elderly patients with coronary heart disease, which can better remove pathogenic bacteria, control various adverse reactions during drug treatment, and ensure the effectiveness and safety of drug use

    Similar works